Circulating miRNAs Respond to Denosumab Treatment after Two Years in Postmenopausal Women with Osteoporosis.

Zora MessnerDavid Carro-VazquezJudith HaschkaJohannes GrillariHeinrich ReschChristian MuschitzPeter PietschmannJochen ZwerinaMatthias HacklRoland Kocijan

Published in: The Journal of clinical endocrinology and metabolism (2022)

Two years of DMAB-treatment resulted in the upregulation of 7 miRNAs, four of which are mainly transcribed in monocytes indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB-treatment response.

Keyphrases

bone mineral density
induced apoptosis
postmenopausal women
signaling pathway
poor prognosis
dendritic cells
cell death
body composition
peripheral blood
replacement therapy